News | January 18, 2007

Study Aimed at Causes, Prevention of PAD

Jan. 19, 2007 — The University of Pennsylvania Health System and Life Line Screening, the nation's largest provider of mobile preventive health screenings, are collaborating to identify and recruit patients with Peripheral Arterial Disease (P.A.D.) for a pilot study on the causes and prevention of this common yet under-treated vascular disease.

"P.A.D. has a strong correlation to coronary heart disease and carries a higher risk of stroke and heart attack," says Dr. Emile R. Mohler III, director of Vascular Medicine, University of Pennsylvania Health System. "As we develop a greater understanding of how P.A.D. progresses, we'll be better equipped to help patients by determining when and how to treat them."

Using noninvasive ultrasound imaging, the research will begin to pinpoint the exact cause and progression of claudication, or outward symptoms of P.A.D., which include cramps, tiredness or pain in the legs and buttocks occurring when blood flow is restricted by atherosclerosis

For more information visit www.lifelinescreening.com.

Related Content

The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

Feature | Peripheral Artery Disease (PAD) | January 30, 2019 | Dave Fornell, Editor
In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat...
The safety of paclitaxel-eluting stents and drug-coated balloons were called into question in a recent study that showed higher mortality rates after two years. The Boston Scientific Eluvia paclitaxel-eluting peripheral stent is among the devices included in that study, but recent trial data for Eluvia show the device is very safe and has good outcomes. FDA warns about use of paclitaxel-eluting  stents and balloons.

The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Boston Scientific Eluvia paclitaxel-eluting peripheral stent is among the devices included in that study, but recent trial data for Eluvia show the device is very safe.

Feature | Peripheral Artery Disease (PAD) | January 25, 2019 | Dave Fornell, Editor
The anti-proliferative drug paclitaxel has been used as a coating on coronary stents to prevent restenosis since 2003
Lumee Oxygen Platform Measures Treatment Response in Critical Limb Ischemia
News | Peripheral Artery Disease (PAD) | January 25, 2019
January 25, 2019 — Profusa announced promising...
BEST-CLI Trial Examining Critical Limb Ischemia Treatment Options Nears Enrollment Goal
News | Peripheral Artery Disease (PAD) | January 23, 2019
A new report in the Journal of Vascular Surgery chronicles a multi-site randomized controlled trial comparing treatment...
FDA Issues Letter About Paclitaxel Coated Balloons and Eluting Stents
News | Peripheral Artery Disease (PAD) | January 17, 2019
The U.S. Food and Drug Administration (FDA) issued a letter Jan. 17, 2019, to healthcare providers regarding a recent...
New Appropriate Use Criteria Released for Peripheral Artery Interventions
News | Peripheral Artery Disease (PAD) | December 19, 2018
A new set of appropriate use criteria (AUC) released Dec. 17 by a group of cardiovascular professional societies...
Lithotripsy Safe and Effective in Calcified Stenotic Peripheral Arteries
News | Peripheral Artery Disease (PAD) | December 04, 2018
New results from the DISRUPT PAD II study showed no perforations, embolization, reflow or abrupt closures with the...
Lutonix 014 Drug-Coated Balloon Safe and Effective Below the Knee
News | Peripheral Artery Disease (PAD) | November 07, 2018
The Lutonix Drug-Coated Balloon (DCB) showed statistically significant safety equivalence with a standard percutaneous...
Lokai Medical to Distribute NuCryo Vascular PolarCath Balloon Dilatation System in U.S.
News | Peripheral Artery Disease (PAD) | August 14, 2018
NuCryo Vascular announced that the company has signed a commercialization agreement with Lokai Medical, a specialty...
Overlay Init